HCAR2 Protéine

N° du produit ABIN7538324

Cette protéine Synthetic Nanodisc HCAR2 est produite dans Mammalian Cells.

Aperçu rapide pour HCAR2 Protéine (ABIN7538324)

Antigène: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Type de proteíne: Synthetic Nanodisc

Origine: Humain

Source: Mammalian Cells

Détail du produit

Fonction: Human HCAR2 full length protein-synthetic nanodisc

Attributs du produit: Unlike other membrane scaffold protein (MSP) Nanodisc on the market, our synthetic Nanodisc can be prepared directly from the cells. The polymers used during this process have a dual function. It dissolves the cell membranes, like the detergent, and uses cellular phospholipids to form Nanodisc around the membrane proteins. The target protein embedded Nanodiscs can then be purified.

Information d'application

Commentaires:

Advantages of Synthetic Nanodiscs:

• Highly purified membrane proteins
• High solubility in aqueous solutions
• High stability
• Proteins are in a native membrane environment and remain biologically active
• No detergent and can be used for cell-based assays
• No MSP backbone proteins

Limitations of Synthetic Nanodiscs:

• Intolerant to acids and high concentrations of divalent metal ions

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Date de péremption: 12 months

Détail du antigène

Antigène: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Autre désignation: HCAR2

Sujet: Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.[UniProtKB/Swiss-Prot Function]

Poids moléculaire: The human full length HCAR2 protein has a MW of 41.9kDa

UniProt: Q8TDS4